Zoledronic Acid

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Zoledronic Acid
   1. Pharmacist Assessment Report
   2. Zoledronic Acid: Known uses and market status in Australia
   3. Summary
   4. Quick overview
   5. Known uses among the model’s candidates
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Australia Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Zoledronic Acid: Known uses and market status in Australia

Summary

All candidates that the TxGNN deep-learning model produced for Zoledronic Acid (score ≥ 0.99) and that can be traced to a source are already known uses. There is therefore currently no new predicted indication for this drug. The one known use is recorded as a knowledge graph relation.

Quick overview

Item	Content
New predicted indications	None (all traceable model candidates are known uses)
Known uses among model candidates	1
Evidence level	Not applicable
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)

Known uses among the model’s candidates

Approved (supported by a licence or label)

Indication	Source
none	none

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
bone Paget disease

Australia Market Information

Licence	Product	Dosage form	Status
13772W	DEZTRON	Injection concentrate for I.V. infusion	Valid

Safety Considerations

• Conditions linked to contraindication or caution (knowledge graph, not label text): anuria, hypercalcaemia, nephrocalcinosis, phosphorus metabolism disease, impaired renal function, intracranial haemorrhage, osteonecrosis of the jaw, hypophosphataemia, hypoparathyroidism, pulmonary oedema, fibromyalgia, myositis, tooth disease.
• Drug interactions: 100 interactions were found. Moderate-level examples include amphotericin B (including lipid, cholesteryl sulfate and liposomal forms), aminoglycosides (kanamycin, neomycin, streptomycin), vancomycin, polymyxin B, aspirin, mesalazine, balsalazide, olsalazine, sulfasalazine and exenatide. Several interact through additive renal or electrolyte effects. Interactions with unknown severity include calcitriol, vitamin A, pantoprazole, glimepiride and doxycycline.
• Calcium and vitamin D: Published case reports describe prolonged or severe hypocalcaemia after zoledronic acid, particularly with vitamin D deficiency. Vitamin D and calcium status should be corrected before use.

Please refer to the TGA-approved Product Information (PI) for full warnings and contraindications.

---

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---